OXB acquires commercial-scale viral vector facility in North Carolina for $4.5M

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating. The acquisition expands OXB’s viral vector manufacturing capabilities in the US up to commercial-scale, increasing GMP capacity and enhancing services to clients across North America. The FDA approved facility in Durham, North Carolina adds scalable vector manufacturing capabilities and end-to-end services across drug substance and ...